It is used in the treatment of AML and, specifically, its FDA-approved indications are favorable, intermediate, or unknown cytogenetic groups, patients with CD33+-expressing leukemic blasts and, finally, as a frontline treatment with intensive chemotherapy [18]. Here, CD33 is linked to acute myeloid leukemia.